Open Monoclonal Technology
	Developer of human monoclonal antibody platforms. The company develops human therapeutic antibodies based on transgenic rats for pharmaceutical companies.
	['', 'human monoclonal', ' ', 'antibody platform', ' ', 'transgenic rat', '']
GLYCART Biotechnology
	Developer of antibody based products for the treatment of unmet clinical needs such as cancer. The company focuses on the development and commercialization of a new generation of antibody products based on its proprietary GlycoMAb technology.
	['antibody ', 'antibody products', '']
Centocor
	Developer of monoclonal antibody technology. The company develops monoclonal antibody-based products for cardiovascular and autoimmune diseases, cancer and inflammation.
	['', 'monoclonal antibody technology', ' ', 'autoimmune disease', ' biopharmaceutical']
Merrimack Pharmaceuticals
	Provider of commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The company develops MM-093, a human alpha-fetoprotein for the treatment of patients with rheumatoid arthritis and psoriasis and MM-121, a human monoclonal antibody and therapeutic to block signaling of the ErbB3 receptor.
	['', 'commercial medicine', ' ', 'diagnostic treatment', ' cancer']
FivePrime Therapeutics
	Developer of protein and antibody therapeutics. The company\'s products include protein based therapeutics for oncology, metabolic disease, type II diabetes, acute myocardial infarction, intestinal bowel disease and infectious diseases and cancer immunotherapy disease areas.
	['', 'antibody therapeutic', ' ', 'cancer immunotherapy', ' ', 'protein therapeutic', '']
4-Antibody
	Developer of an antibody drug discovery platform. The company is a biopharmaceutical enterprise developing a fully human, antibody drug discovery platform. The company is making this technology available to pharmaceutical partners, as well as developing a proprietary pipeline of antibody oncology drugs.
	['', 'discovery technology platform', ' immunotherapy ', 'antibody drug', '']
Affomix
	Developer of antibody-based products.
	['', 'antibody screening', ' ', 'antibody product', ' ', 'antibody preparation', '']
Domantis
	Developer of antibody molecules for therapy. It offers dual targeting human domain antibodies, which are used against cytokine targets for inflammatory diseases, tumour antigens present on the same tumour cells, and tumour growth/angiogenic factors for solid tumours; human domain antibodies with tailored serum half-life that are customized to achieve the desired therapeutic effect; human domain antibodies for diverse therapeutic targets, which are suited to inhibit receptor targets; and injectable and non-injectable human domain antibodies that treat diseases of the lung, as well as disorders of the gastro-intestinal tract.
	['', 'antibody therapeutic', ' ', 'domain antibody', ' ', 'antibody molecules', ' ', 'antibody molecules for therapy', ' ', 'dual targeting human domain antibodies', ' ', 'human domain antibodies', ' ', 'disease therapy', ' ', 'tumor therapy', ' ', 'disease therapy', '']
Cytheris
	Developer of therapies for immune modulation. The company offers drugs focused for lymphopenic patients. The company\'s product helps to enhance the immune system of cancer and chronic viral patients.
	['', 'immune modulation', ' oncology']
CellMed
	Developer of a biological drug delivery system for therapeutic treatment. The company\'s core product is CellMed UHVBiopolymer, which is used as a material to encapsulate cells and tissue. The company\'s products are marketed as CellBeads, which are micro-implants that produces therapeutic molecules to treat diseases like hypoparathyroidism, diabetes, oncology and neurodegeneration.
	['', 'therapeutic treatment', ' CellBeads ', 'micro-implants', ' ', 'therapeutic molecules', '']
Nereus Pharmaceuticals
	Developer of therapeutic drugs for the treatment of cancer. The company is engaged in discovery and development of therapeutic medicines and drugs which are used in the treatment of tumors, cancer, colon, prostate and other inflammatory diseases.
	['', 'marine microbiology technology', '  therapeutic ', 'development of therapeutic', ' ', 'treatment of oncology', '']
Morphosys
	MorphoSys AG and its subsidiaries develops and commercializes antibodies for therapeutic applications. It also develops drugs together with its partners in the pharmaceutical and biotechnology industries.
	['', 'antibody technology', ' ', 'human antibody', ' ', 'therapeutic antibody', '']
Targeted Molecules
	Developer of drug therapies for cancer and diseases of the central nervous system. The company\'s technology enables both the identification and optimization\nof molecules (peptides and antibody fragments) that precisely target disease tissue.
	['', 'drug therapies', ' ', 'targeted therapeutic', ' ', 'identification and optimization of molecules', '']
Automated Cell
	Developer of antibody therapeutic antibodies for the treatment of oncology and immune disease. The company is focused on the development of monoclonal antibody therapeutics for the treatment of cancer.
	['', 'antibody therapeutic', ' ', 'therapeutic treatment', ' ', 'oncology disease', ' ', 'immune disease', ' ', 'monoclonal antibody', '']
Applied Genomics
	Developer of targeted genomics-based diagnostic and therapeutic antibodies for the treatment of human cancer. The company\'s products include Mammostrat which is an immunohistochemistry breast cancer prognostic test, Mammotax which is a single antibody immunohistochemistry test, Pulmotype is a five antibody immunohistochemistry aid for the classification of non-small cell lung cancer and Pulmostrat is a seven antibody prognostic immunohistochemistry test.
	['', 'human cancer', ' ', 'therapeutic antibodies', ' ', 'diagnostic devices', '']
GITR
	Developer of oncological therapies. The company is developing TRX518, a humanized monoclonal antibody that is reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR), for the treatment of cancer.
	['', 'chemotherapeutic treatment', ' ', 'tumor markers', ' ', 'T cell', '']
Immunologix
	Developer of antibody-based therapeutics. The company provides methods for producing human monoclonal antibodies against any target including bacterial and viral antigens, as well as tumor antigens, and human autoantigens. Its technology allows for the conversion of na√Øve B-cells (from a tonsillectomy or whole blood collection) to fully mature human B-cells producing the human antibody of interest.
	['', 'antibody therapeutic', ' ', 'human monoclonal', ' ', 'therapeutic device', '']
Adnexus Therapeutics
	Developer of Adnectins biologics/medicines in the United States. The company\'s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases.
	['', 'drug discovey', ' ', 'anti-angiogenesis agent', ' ', 'treatment of oncology', '']
